Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Tanios Bekaii‐Saab(AstraZeneca (United Kingdom)), Miguel A. Villalona‐Calero(AstraZeneca (United Kingdom))
Cited by 304
Related Papers
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
|JAMA Network Open|2022|121
MicroRNA‐34a is an important component of PRIMA‐1‐induced apoptotic network in human lung cancer cells
|International Journal of Cancer|2009|27
MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers
|Scientific Reports|2021|5